advanc
occur
surgic
techniqu
postop
care
immunosuppress
therapi
rate
mortal
earli
postop
period
follow
lung
transplant
continu
declin
improv
immedi
earli
posttranspl
mortal
infect
sequel
well
reject
chronic
allograft
dysfunct
increasingli
major
caus
posttranspl
mortal
chapter
focu
infect
respiratori
virus
viral
infect
relev
lung
transplant
includ
data
regard
link
viral
infect
allograft
dysfunct
lung
prone
infect
solid
organ
transplant
realiti
base
multipl
factor
relat
uniqu
lung
transplant
lung
continu
expos
new
environment
pathogen
colon
nativ
upper
airway
furthermor
mani
natur
defens
mechan
respiratori
system
made
ineffect
technic
aspect
lung
transplant
rel
increas
degre
immunosuppress
requir
minim
high
rate
acut
chronic
reject
seen
lung
transplant
compar
solid
organ
usual
physic
barrier
respiratori
tract
infect
includ
presenc
mucociliari
escal
trap
expel
infecti
organ
mechan
facilit
integr
epithelium
line
trachea
bronchi
small
airway
complet
disrupt
bronchial
circul
lung
transplant
caus
loss
epithelium
integr
associ
mucociliari
action
may
fulli
recov
despit
develop
collater
flow
futur
addit
compromis
anatom
barrier
infect
creat
potenti
suppress
cough
reflex
caus
denerv
allograft
disrupt
normal
lymphat
flow
lung
transplant
also
increas
risk
infect
creat
edema
stasi
interstiti
fluid
incid
allograft
dysfunct
due
acut
chronic
reject
lung
transplant
among
highest
solid
transplant
requir
rel
high
level
immunosuppress
target
multipl
line
immun
cell
associ
cytokin
pathway
use
induct
high
level
mainten
immunosuppress
creat
signific
risk
develop
viral
infect
higher
tacrolimu
level
specif
associ
increas
rate
carv
infect
prevent
suppress
infect
respiratori
virus
involv
activ
cellular
antibodymedi
immun
impair
immunosuppress
target
adapt
tcellmedi
process
point
highlight
rel
weak
antibodi
respons
vaccin
direct
certain
respiratori
virus
recipi
solid
organ
transplant
transmiss
donorharbor
infect
time
transplant
anoth
factor
increas
likelihood
viral
infect
ltr
mani
virus
highest
risk
develop
activ
diseas
exist
circumst
recipi
prior
exposur
establish
humor
immun
viru
mismatch
donor
whose
tissu
harbor
activ
infect
latent
form
viru
viral
infect
previous
document
origin
donor
lung
tissu
includ
cmv
epsteinbarr
viru
varicellazost
adenoviru
influenza
hepat
b
c
human
immunodefici
viru
addit
other
therefor
center
evalu
donor
lung
transplant
routin
includ
serolog
screen
common
virus
well
bronchoscop
assess
pcr
analysi
bal
sampl
common
respiratori
virus
reactiv
latent
viru
previous
introduc
ltr
follow
induct
mainten
immunosuppress
therapi
anoth
risk
factor
clinic
signific
viral
infect
reason
initi
pretranspl
candid
evalu
process
includ
thorough
screen
mani
virus
list
addit
help
determin
patient
candidaci
transplant
screen
help
determin
need
durat
antivir
prophylaxi
specif
virus
posttransplant
period
infect
previous
latent
virus
donor
recipi
tissu
signific
concern
earli
posttransplant
period
howev
period
sever
month
posttransplant
repres
risk
viral
infect
phenomenon
relat
primarili
return
commun
life
ltr
recov
initi
surgic
cours
subsequ
physiolog
infecti
insult
evid
suggest
ltr
greater
year
surgeri
five
time
like
present
carv
infect
compar
less
year
transplant
respiratori
virus
member
herpesvirida
famili
frequent
caus
clinic
signific
infect
potenti
sever
complic
solid
organ
transplant
sot
advanc
field
diagnost
virolog
primarili
base
new
molecular
assay
greatli
improv
breadth
sensit
detect
method
viral
infect
multiplex
pcr
assay
avail
fdaapprov
nearli
decad
provid
significantli
larger
number
small
laboratori
without
expertis
viral
cultur
techniqu
opportun
particip
real
time
diagnosi
wide
array
respiratori
viral
pathogen
furthermor
new
multiplex
pcrbase
assay
abl
provid
rapid
sensit
identif
respiratori
virus
tradit
viral
cultur
immunofluoresc
test
last
decad
sever
new
viral
respiratori
tract
pathogen
identifi
includ
human
metapneumoviru
hmpv
human
bocaviru
hbov
new
strain
human
coronaviru
new
speci
rhinoviru
hrvc
develop
chronic
lung
allograft
reject
clad
encount
bronchiol
obliteran
syndrom
bo
restrict
chronic
lung
allograft
dysfunct
rclad
continu
primari
driver
mortal
ltr
first
year
follow
transplant
oblit
bronchiol
hallmark
bo
appear
patholog
endstag
process
initi
begin
airway
epitheli
injuri
lead
inflammatori
reaction
promot
airway
obliter
incit
injuri
epithelium
may
initi
exposur
toxic
chemic
drug
infect
includ
viral
agent
autoimmun
process
airway
inflamm
injuri
result
number
sever
episod
acut
reject
also
thought
play
import
role
develop
clad
viral
infect
process
lead
allograft
reject
previous
document
solid
organ
transplant
renal
allograft
dysfunct
caus
infect
bk
viru
cmv
similarli
multipl
studi
last
two
decad
indic
respiratori
viral
infect
play
major
role
develop
acut
reject
chronic
lung
allograft
dysfunct
manifest
bo
rclad
find
appli
cmv
noncmv
respiratori
virus
symptomat
asymptomat
respiratori
viru
infect
rvi
past
remark
high
rate
patholog
document
graft
chang
suggest
acut
reject
report
set
activ
respiratori
viral
infect
seri
mani
case
respiratori
viru
infect
ltr
note
vari
degre
perivascular
mononuclear
cell
infiltr
seen
acut
cellular
reject
find
support
cohort
studi
higher
incid
bo
note
ltr
suffer
carv
infect
reproduc
differ
set
acut
longterm
outcom
respiratori
viral
infect
declin
allograft
function
document
case
relationship
seen
factor
like
associ
develop
graft
dysfunct
includ
respiratori
viru
infect
involv
lower
respiratori
tract
infect
virus
known
caus
sever
respiratori
ill
gener
influenza
paramyxovirus
relationship
viral
infect
respiratori
tract
develop
allograft
reject
would
seem
base
similar
pathogenesi
process
acut
phase
viral
infect
well
prolong
viral
shed
often
seen
set
lung
transplant
chemotact
cytokin
releas
injur
parenchym
cell
inflam
graft
recruit
alloreact
leukocyt
process
augment
immun
respons
specif
target
viru
process
tcell
subtyp
associ
cytokin
interleukin
il
tumor
necrosi
factor
upregul
result
alloreact
environ
transplant
lung
may
lead
immunemedi
injuri
airway
subsequ
reject
graft
dysfunct
recent
lung
transplant
literatur
activ
receptor
express
surfac
activ
lymphocyt
provid
evid
support
role
viral
infect
develop
lymphocytemedi
allograft
dysfunct
receptor
ligand
role
immun
respons
virus
develop
bo
set
carv
infect
ltr
concentr
ligand
increas
associ
larger
declin
month
case
cmv
specif
member
carv
group
interplay
viralassoci
chang
host
immun
factor
form
pathophysiolog
relationship
promot
develop
allograft
dysfunct
cytokin
cascad
induc
activ
cmv
infect
well
cytokin
involv
pathophysiolog
reject
promot
progress
one
anoth
releas
tumor
necrosi
factoralpha
allograft
reject
act
key
reactiv
signal
latent
cmv
facilit
viral
replic
progress
activ
infect
meanwhil
activ
cmv
within
vascular
endothelium
smooth
muscl
induc
upregul
adhes
molecul
promot
prolifer
activ
inflammatori
cell
graft
lead
develop
reject
cmv
thought
play
addit
role
develop
reject
process
molecular
mimicri
immun
respons
viral
antigen
lead
product
antiendotheli
antibodi
within
graft
carv
repres
divers
group
human
pathogen
virus
belong
sever
distinct
famili
includ
paramyxovirida
rsv
hmpv
piv
orthomyxovirida
influenza
b
picornavirida
rhinoviru
enterovirus
adenovirida
adenoviru
coronavirida
coronavirus
virus
repres
common
caus
human
respiratori
infect
commonli
acquir
contact
infect
individu
secret
left
environ
infect
person
mode
transmiss
includ
contact
secret
follow
autoinocul
mucos
membran
versu
direct
inocul
larg
droplet
aerosol
infect
pattern
organ
follow
typic
season
tempor
pattern
case
tend
mirror
pattern
gener
commun
healthcareassoci
infect
also
occur
even
exhibit
case
outbreak
within
hospit
carv
infect
lead
seriou
complic
predispos
factor
immunosuppress
alter
pulmonari
anatom
defens
mechan
ltr
particularli
high
risk
develop
sever
infect
infect
respiratori
tract
carv
ltr
complic
occurr
secondari
bacteri
infect
increas
incid
associ
acut
chronic
reject
picornavirus
primarili
rhv
common
virus
found
nasopharyng
bal
sampl
collect
ltr
bit
routin
screen
healthcar
visit
specif
respiratori
infecti
symptom
common
carv
rhv
much
like
isol
emerg
visit
routin
screen
suggest
higher
incid
symptomat
infect
gener
ltr
popul
high
incid
posit
test
carv
infect
surveil
screen
without
symptom
nearli
doubl
rate
test
present
symptom
acut
respiratori
ill
spectrum
diseas
sever
carv
infect
ltr
vari
significantli
depend
specif
infecti
agent
rhv
infect
common
carv
often
present
limit
symptom
found
asymptomat
screen
one
third
case
common
symptom
rhv
infect
includ
rhinorrhea
nasal
congest
fever
myalgia
rel
uncommon
meanwhil
infect
influenza
paramyxovirus
rsv
piv
almost
alway
associ
symptom
much
like
febril
ill
lower
respiratori
tract
involv
radiograph
manifest
typic
rare
except
case
influenza
infect
influenza
paramyxovirus
also
twice
like
result
hospit
compar
rhv
coronaviru
nearli
case
requir
admiss
nearli
case
symptomat
infect
carv
lower
fvc
seen
compar
preinfect
valu
patient
current
vaccin
antivir
prophylact
regimen
rsv
multipl
clinic
trial
assess
effect
innov
rsv
vaccin
pavilizumab
recommend
prophylaxi
children
meet
treatment
criteria
use
medic
prevent
rsv
older
transplant
recipi
recommend
limit
data
regard
role
antivir
therapi
treat
rsv
lung
transplant
recipi
current
drug
choic
ribavirin
without
corticosteroid
administ
intraven
oral
inhal
tabl
treatment
decis
commonli
depend
sever
diseas
inhal
ribavirin
often
rout
choic
sever
rsv
infect
inhal
ribavirin
mani
drawback
administr
requir
hospit
admiss
extend
inhal
interv
teratogen
women
childbear
age
factor
medic
appropri
precaut
taken
intraven
ribavirin
report
success
although
avail
compassion
use
unit
state
adjunct
therapi
use
pavilizumab
intraven
immunoglobulin
use
littl
publish
efficaci
lastli
presatovir
medic
undergo
phase
ii
clinic
trial
assess
efficaci
novel
antivir
agent
treatment
rsv
infect
lung
transplant
patient
known
vaccin
prophylact
antivir
medic
known
prevent
parainfluenza
current
proven
treatment
parainfluenza
viral
infect
ribavirin
steroid
ivig
use
treat
parainfluenza
infect
transplant
recipi
proven
provid
benefit
novel
sialidas
fusion
protein
use
compassion
use
current
phase
ii
trial
treatment
parainfluenza
immunocompromis
patient
hmpv
rel
new
addit
paramyxoviru
famili
hmpv
present
clinic
spectrum
diseas
similar
rsv
albeit
typic
less
sever
diseas
sever
rang
asymptomat
infect
sever
lower
respiratori
tract
infect
current
data
support
associ
hmpv
infect
develop
persist
allograft
dysfunct
case
rsv
howev
evid
acut
declin
lung
function
follow
hmpv
infect
exist
immunogen
influenza
vaccin
lung
transplant
recipi
unknown
even
season
influenza
vaccin
recommend
transplant
patient
along
immun
transplant
patient
herd
immun
import
strategi
come
posttranspl
patient
care
therefor
essenti
ensur
close
contact
lung
transplant
recipi
also
vaccin
two
type
influenza
vaccin
avail
intranas
live
attenu
influenza
vaccin
intramuscular
inactiv
vaccin
live
attenu
vaccin
contraind
transplant
recipi
therefor
inactiv
vaccin
administ
due
intens
immunosuppress
directli
posttranspl
concern
decreas
immunogen
vaccin
often
withheld
directli
transplant
accord
american
societi
transplant
reason
time
frame
wait
least
month
transplant
influenza
vaccin
administr
postexposur
prophylaxi
oseltamivir
zanamivir
may
indic
transplant
recipi
expos
influenza
primarili
exposur
someon
live
household
prophylaxi
initi
patient
present
within
h
exposur
oseltamivir
h
exposur
zanamivir
see
tabl
prophylaxi
dose
durat
two
class
antivir
use
treat
influenza
inhibitor
amantadin
rimantadin
neuraminidas
inhibitor
oseltamivir
zanamivir
peramivir
neuraminidas
inhibitor
prefer
agent
treat
influenza
inhibitor
longer
recommend
due
increas
resist
inact
influenza
b
respect
oseltamivir
commerci
avail
capsul
suspens
zanamivir
administ
inhal
peramivir
infus
current
iv
formul
zanamivir
oseltamivir
avail
investig
use
commerci
avail
oseltamivir
use
antivir
treat
influenza
lung
transplant
popul
zanamivir
peramivir
lack
data
sever
diseas
treatment
hospit
patient
usual
durat
therapi
influenza
b
treatment
day
although
immunosuppress
patient
includ
lung
transplant
recipi
may
prolong
viral
replic
also
increas
risk
develop
antivir
resist
therefor
longer
durat
therapi
consid
dose
durat
therapi
present
tabl
rhv
common
caus
cold
adult
member
picornavirida
famili
much
like
gener
popul
rhv
increasingli
recogn
common
caus
respiratori
viral
ill
ltr
addit
mani
pcrdocument
case
rhv
infect
transplant
recipi
symptom
time
surveil
test
typic
clinic
present
involv
afebril
upper
respiratori
ill
rhinorrhea
sinu
congest
sometim
associ
sore
throat
cough
coinfect
pathogen
complic
mani
case
rhv
infect
ltr
may
contribut
significantli
rel
high
morbid
mortal
rate
observ
incid
rhvassoci
lower
respiratori
tract
infect
ltr
document
contrast
typic
mild
selflimit
diseas
gener
popul
event
associ
risk
acut
chronic
reject
increas
mortal
current
specif
prophylact
treatment
option
avail
rhv
vaccin
establish
chemoprophylaxi
prevent
adenoviru
solid
organ
transplant
recipi
current
random
control
trial
regard
treatment
sever
adenoviru
infect
current
prefer
therapi
center
minim
immunosuppress
antivir
need
cidofovir
consid
drug
util
caution
cidofovir
administr
associ
signific
advers
reaction
primarili
neutropenia
nephrotox
pronounc
lung
transplant
order
mitig
nephrotox
caus
cidofovir
probenacid
hydrat
ad
regimen
probenacid
administ
h
h
h
cidofovir
along
hydrat
normal
salin
adjunct
reduc
immunosuppress
without
cidofovir
immunoglobulin
may
consid
primarili
patient
hypogammaglobinemia
although
benefit
ivig
set
adenoviru
infect
without
hypogammaglobinemia
still
clear
futur
brincidofovir
lipid
conjug
cidofovir
current
clinic
trial
may
viabl
option
benefit
dosag
form
may
includ
oral
formul
higher
potenc
less
nephrotox
coronavirus
frequent
caus
common
cold
current
unclear
role
infect
affect
ltr
new
sensit
molecular
assay
detect
coronaviru
infect
help
detect
viru
rang
simpl
upper
respiratori
ill
sever
lower
respiratori
tract
infect
sever
infect
immunocompromis
present
pneumonia
bronchiol
similar
rhv
infect
current
pharmacolog
option
prophylaxi
treatment
avail
herpesvirida
heterogen
famili
morpholog
similar
doublestrand
dna
virus
infect
human
anim
human
act
primari
host
eight
member
viru
famili
typic
transmit
direct
persontoperson
contact
cmv
infect
diseas
distinct
clinic
entiti
replic
cmv
without
symptom
regard
infect
presenc
symptom
physiolog
chang
attribut
cmv
requir
meet
definit
diseas
hallmark
cmv
diseas
includ
fever
malais
myalgia
arthralgia
leukopenia
thrombocytopenia
well
tissu
invas
manifest
tissu
invas
diseas
commonli
manifest
pneumon
syndrom
present
subtl
fever
nonproduct
cough
dyspnea
associ
declin
pulmonari
function
test
manifest
tissu
invas
diseas
includ
incid
hepat
associ
abnorm
liver
function
test
gastroenter
coliti
typic
present
nausea
vomit
diarrhea
quantit
nucleic
acidbas
amplif
assay
util
polymeras
chain
reaction
pcr
technolog
identif
viremia
larg
replac
previous
use
method
diagnosi
reli
antigen
detect
viral
particl
monitor
diagnosi
cmv
infect
use
overwhelm
major
transplant
center
despit
current
consensu
threshold
valu
cmv
viral
load
consid
indic
infect
viral
cultur
perform
blood
urin
bal
sampl
longer
routin
recommend
detect
cmv
presenc
cellmedi
immun
cmv
determin
quantiferoncmv
assay
measur
presenc
tcell
respons
viru
hold
promis
marker
determin
risk
cmv
diseas
patient
posit
cmv
interferongamma
releas
assay
shown
frequent
clear
viremia
without
progress
clinic
diseas
neg
assay
suffer
higher
rate
late
onset
cmv
diseas
discontinu
prophylact
therapi
intraven
ganciclovir
histor
treatment
choic
treatment
cmv
iv
formul
still
drug
choic
sever
lifethreaten
diseas
patient
sever
diarrhea
toler
medic
mouth
victor
studi
group
conclud
oral
valganciclovir
also
treatment
option
select
solid
organ
transplant
recipi
mild
moder
diseas
although
note
less
patient
victor
studi
lung
transplant
recipi
patient
sever
diseas
whether
use
intraven
ganciclovir
oral
valganciclovir
treatment
continu
day
plu
viral
clearanc
viru
clear
day
high
risk
recurr
diseas
therefor
longer
durat
may
necessari
resolut
viremia
accomplish
tabl
outlin
dose
guidelin
adjust
renal
function
ganciclovir
valganciclovir
chemoprophylaxi
cmv
start
soon
possibl
alway
within
day
transplant
risk
cmv
recommend
prophylaxi
cmv
diseas
lung
transplant
recipi
base
donor
recipi
igg
serostatu
tabl
patient
highest
risk
develop
cmv
diseas
donor
igg
posit
recipi
igg
neg
prophylaxi
iv
ganciclovir
valganciclovir
combin
recommend
durat
prophylaxi
vari
least
month
prophylaxi
recommend
center
extend
prophylaxi
beyond
month
adjunct
chemoprophylaxi
cmv
immun
globulin
also
consid
highrisk
group
patient
moderaterisk
recipi
igg
seroposit
recipi
iv
ganciclovir
valganciclovir
recommend
month
lowrisk
donor
recipi
igg
seroneg
neg
patient
cmvspecif
prophylaxi
necessari
hsv
prophylaxi
acyclovir
still
indic
neither
ganciclovir
valganciclovir
requir
tabl
preemptiv
therapi
ie
withhold
valganciclovir
iv
ganciclovir
prophylaxi
monitor
patient
weekli
basi
cmv
viremia
treat
prevent
diseas
progress
gener
recommend
lung
transplant
recipi
emerg
concern
manag
ganciclovirresist
cmv
diseas
ganciclovir
resist
associ
high
morbid
mortal
option
come
treatment
current
drug
choic
either
foscarnet
cidofovir
highli
toxic
requir
extend
hospit
initi
therapi
resist
usual
due
mutat
gene
less
commonli
gene
mutat
confer
resist
cidofovir
foscarnet
mutat
may
confer
resist
three
medic
therefor
difficult
treat
mani
time
adjunct
cidofovir
foscarnet
transplant
center
consid
discontinu
current
antimetabolit
initi
leflunomid
antivir
antimetabolit
properti
futur
option
treatment
cmv
includ
maribavir
brincidofovir
current
clinic
trial
avail
use
matter
situat
treatment
ganciclovirresist
cmv
undertaken
caution
case
case
basi
overal
immunosuppress
play
vital
role
ebv
ptld
occurr
use
lymphocytedeplet
therapi
link
increas
ptld
case
consid
discuss
use
lymphocytedeplet
induct
treatment
approach
order
prevent
reject
minim
risk
ptld
acyclovir
ganciclovir
vitro
activ
ebv
lytic
replic
use
prophylaxi
although
efficaci
proven
anoth
approach
monitor
ebv
viral
load
serial
pcr
posttranspl
follow
allow
center
preemptiv
add
chemoprophylaxi
decreas
immunosuppress
trend
viral
load
prophylact
strategi
efficaci
ebv
monitor
preemptiv
intervent
decreas
occurr
ptld
posttranspl
establish
minim
immunosuppress
mainstay
manag
ebv
ptld
reduc
immunosuppress
reconstitut
cytotox
tcell
popul
thought
control
ebv
infect
bcell
popul
addit
antivir
medic
combin
reduc
immunosuppress
patient
ptld
controversi
primarili
due
major
ebv
within
ptld
mass
undergo
lytic
infect
therefor
util
antivir
therapi
well
defin
ivig
also
consid
adjunct
therapi
treatment
regimen
although
benefit
addit
ivig
establish
treatment
rituximab
without
tradit
chemotherapi
option
depend
sever
diseas
patient
respons
reduc
immunosuppress
usual
regimen
similar
bcell
lymphoma
often
requir
chop
even
treatment
option
ptld
lung
transplant
recipi
remain
high
caus
morbid
mortal
recent
singl
center
report
approxim
patient
treat
rituximabbas
therapi
full
remiss
diseas
respons
treatment
surviv
ptld
diagnosi
due
complex
transplant
sever
ptld
multidisciplinari
approach
often
benefici
patient
transplant
care
provid
along
cancer
treatment
center
devis
plan
would
best
fit
individu
patient
maxim
outcom
qualiti
life
prior
list
transplant
candid
evalu
varicella
seroposit
seroneg
patient
commonli
consid
varicella
vaccin
administ
least
day
prior
transplant
varicella
vaccin
liveattenu
vaccin
administ
transplant
therefor
everi
effort
made
vaccin
appropri
patient
prior
transplant
lung
transplant
recipi
receiv
prophylaxi
herp
virus
directli
transplant
patient
receiv
prophylaxi
valganciclovir
cmv
suffici
herp
viru
prophylaxi
patient
requir
cmv
prophylaxi
donor
recipi
seroneg
cmv
acyclovir
valacyclovir
drug
choic
prophylaxi
although
famciclovir
also
accept
tabl
treatment
outpati
oral
antivir
appropri
mucocutan
mild
moder
diseas
lung
transplant
recipi
patient
moder
sever
diseas
hospit
requir
aggress
therapi
transplant
recipi
primarili
diagnos
dissemin
cn
diseas
intraven
acyclovir
drug
choic
tabl
durat
therapi
rang
day
depend
sever
diseas
local
herp
zoster
infect
therapi
continu
least
day
lesion
crust
note
delay
lesion
crust
commonli
seen
transplant
recipi
often
extend
durat
therapi
gener
durat
treatment
mild
moder
hsv
vzv
diseas
recommend
day
day
sever
central
nervou
system
infect
lymphotrop
virus
belong
subfamili
cmv
caus
primari
infect
earli
childhood
patient
undergon
solid
organ
transplant
note
suffer
reactiv
diseas
typic
earli
posttransplant
period
clinic
syndrom
associ
consist
skin
rash
hepat
bone
marrow
suppress
pneumon
encephalopathi
although
sever
infect
vari
major
case
thought
asymptomat
clinic
impact
less
well
character
viru
associ
develop
kaposi
sarcoma
ks
wellcharacter
entiti
follow
sot
heart
renal
liver
transplant
recipi
incid
ks
transplant
unit
state
approxim
major
case
occur
renal
transplant
recipi
case
ks
lesion
confin
skin
mucosa
oropharynx
remaind
exhibit
involv
intern
organ
lymph
node
last
decad
mount
number
case
ks
ltr
brought
recognit
hhv
import
pathogen
set
lung
transplant
ks
consid
rare
malign
ltr
manifest
involv
allograft
bronchial
pleural
diseas
well
cutan
lesion
involv
viscera
gastric
intestin
tract
consid
patient
characterist
skin
lesion
pulmonari
diseas
includ
hemorrhag
pleural
effus
typic
rich
viral
particl
dna
test
furthermor
associ
increas
viremia
progress
pulmonari
ks
previous
describ
although
data
manag
rare
entiti
ltr
limit
case
appear
full
partial
respons
reduct
immunosuppress
small
case
seri
show
respons
therapi
sirolimu
therapi
tradit
use
treatment
ks
includ
convent
chemotherapi
bleomycin
vincristin
doxorubicin
addit
radiat
although
data
regard
therapeut
modal
set
lung
transplant
suscept
vitro
antiherpesvirida
agent
cidofovir
foscarnet
ganciclovir
data
manag
ks
set
hiv
suggest
reduc
risk
develop
ks
howev
data
use
agent
manag
ks
follow
sot
limit
standard
prevent
treatment
bk
viru
lung
transplant
well
establish
although
bk
viru
may
detect
urin
lung
transplant
viuria
shown
effect
renal
function
therefor
decreas
immunosuppress
use
treatment
modal
leflunomid
bk
viru
lung
transplant
establish
standard
care
parvoviru
caus
pure
red
cell
aplasia
commonli
seen
renal
transplant
recipi
shown
occur
rare
complic
lung
transplant
isol
case
report
despit
rel
lack
data
literatur
subject
ubiqu
parvoviru
exposur
commun
warrant
investig
possibl
case
unexplain
isol
anemia
ltr
chronic
lung
allograft
dysfunct
clad
continu
major
caus
morbid
mortal
lung
transplant
virus
especi
commun
respiratori
virus
crv
common
also
major
sourc
morbid
lung
transplant
recipi
import
newli
intens
area
focu
research
interfac
respiratori
virus
respiratori
virom
chronic
reject
improv
techniqu
studi
pathogenesi
type
chronic
reject
well
recent
advanc
metagenom
doubt
place
move
forward
understand
relationship
virus
lung
allograft
reject
also
abl
work
toward
solut
